December 2015

Emerging discoveries of MET chromosomal fusions provide additional promise as therapeutic genomic targets in MET cancer therapy and would need to be tested vigorously.

In this article, Shipra Gandhi, MD, Pallawi Torka, MD, and Francisco J. Hernandez Ilizaliturri, MD summarize the current clinical development of these novel agents in lymphoid malignancies.

In this review, Rodrigo R. Muhoz, MD, William D. Tap, MD, and Sandra P. D'Angelo, MD address the emerging therapeutic strategies aimed at specific molecular targets that could potentially change the approach to patients with soft-tissue sarcomas.